Clinical Effects of ICS in COPD
Reference N Duration Treatment/Day Outcome
Nishimura et al., 1999 30 4 w BDP 3000mcg ? FEV1, ? Sx
O’Brien et al., 2001 24 6 w BDP 1500mcg FEV1 preserved
Thompson et al., 1992 30 6 w BDP 1000mcg ? FEV1, ? bronchitis
Weiner et al., 1995 30 6 w BUD 800mcg ? FEV1, ? prn med
Weiner et al., 1999 168 6 w BUD 1600mcg ? FEV1, ? prn med
Auffarth et al., 1991 21 8 w BUD 1600mcg ? dyspnea
Kerstjens et al., 1993 39 12 w BDP 800mcg ? FEV1
Dompeling et al., 1992 28 52 w BDP 800mcg ? PEF, ? Sx
Paggiaro et al., 1998 281 24 w FP 1000mcg ? FEV1, ? exac
ISOLDE, 2000 751 3 Y FP 1000mcg ? FEV1, ? QoL, ? exac
Euroscope, 1999 1277 3 Y BUD 800mcg ? FEV1, ? exac
Lung Health II, 2000 1116 3 Y TAA 1200mcg ? Sx , ? exac
Sin & Tu, 2001 22620 Varied ? morbidity, mortality
Keatings et al., 1999 13 2 w BUD 1600mcg No ? PFT, Sx, prn med
Culpitt et al., 1999 13 4 w FP 1000mcg No ? PFT, Sx
Engel et al., 1989 18 12 w BUD 800mcg No ? PFT, Sx Watson et al., 1992 14 12 w BUD 1200mcg No ? PFT, Sx
Bourbeau et al., 1998 79 28 w BUD 1600mcg No ? PFT, Sx, QoL
Copenhagen City, 1996 290 3 Y BUD 800mcg No ? PFT, Sx, exac